Peptide hormones

Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

Retrieved on: 
Wednesday, May 26, 2021
Branches of biology, Peptide hormones, Medical specialties, Clinical medicine, Diabetes, Anti-diabetic drugs, Recombinant proteins, Insulin, Amylin, Pramlintide, Obesity, Exenatide

A second combination of pramlintide and exenatide (PramExe), currently in development, also presents promising properties.

Key Points: 
  • A second combination of pramlintide and exenatide (PramExe), currently in development, also presents promising properties.
  • The pumps used are those already marketed for insulin therapy, and in particular patch-pumps, which are easy to use and suitable for this purpose.
  • "We want to establish a new therapeutic paradigm for chronic diseases such as obesity, allowing patients greater control over their treatment, explained Grard Soula, Adocias CEO.
  • "Our next objective is to establish clinical proof-of-concept with good tolerance and efficacy of PramExe administered via pump, while being well-accepted by people suffering from obesity."

Adocia Expands Clinical Development to Obesity with Patent Applications on Short-Acting Multihormonal Combinations Administered by Pumps

Retrieved on: 
Wednesday, May 26, 2021
Clinical medicine, Medical specialties, Branches of biology, Peptide hormones, Recombinant proteins, Insulin, Obesity

These patents relate to combinations of short-acting hormones administered via pump.

Key Points: 
  • These patents relate to combinations of short-acting hormones administered via pump.
  • The pumps used are those already marketed for insulin therapy, and in particular patch-pumps, which are easy to use and suitable for this purpose.
  • "We want to establish a new therapeutic paradigm for chronic diseases such as obesity, allowing patients greater control over their treatment, explained Grard Soula, Adocias CEO.
  • "Our next objective is to establish clinical proof-of-concept with good tolerance and efficacy of PramExe administered via pump, while being well-accepted by people suffering from obesity."

Global Insulin Pens, Syringes, Pumps and Injectors Market Report 2021: Market is Expected to Surpass $25 Billion in 2025 - Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Health, Pharmaceutical, Medicine, Clinical medicine, Diabetes, Medical monitoring, Diabetes management, Peptide hormones, Recombinant proteins, Insulin, Blood glucose monitoring, Glucose meter, Continuous glucose monitor, Insulin pump

The fear of injections causes anxiety in some patients thus causing them to avoid the use of insulin injections and being inconsistent in their insulin uptake.

Key Points: 
  • The fear of injections causes anxiety in some patients thus causing them to avoid the use of insulin injections and being inconsistent in their insulin uptake.
  • It is a diabetes management device that automatically monitors glucose and provides appropriate level insulin doses needed.
  • This pump uses interoperable technology that allows patients to customize their diabetes management devices according to their preferences.
  • These devices contain automated insulin dosing systems, continuous glucose monitors, blood glucose meters, or other electronic devices.\n'

Leucadia Pharmaceuticals Launches Calcitonin Salmon Injection

Retrieved on: 
Friday, May 21, 2021
Peptide hormones, Branches of biology, Calcitonin, Thyroid, Hormones, Endocrine system, Leucadia

b'CARLSBAD, Calif., May 20, 2021 /PRNewswire/ -- Leucadia Pharmaceuticals , a U.S. leader in generic injectables and the commercial arm of Custopharm, Inc. , today announced the launch of its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic.

Key Points: 
  • b'CARLSBAD, Calif., May 20, 2021 /PRNewswire/ -- Leucadia Pharmaceuticals , a U.S. leader in generic injectables and the commercial arm of Custopharm, Inc. , today announced the launch of its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic.
  • "Calcitonin Salmon Injection, USP once again demonstrates Leucadia\'s commitment to the development and launch of critically needed, lower cost therapies in the generic injectables market.
  • "\nLeucadia Pharmaceuticals\' Calcitonin Salmon Injection, USP, Synthetic FDA approval includes a Competitive Generic Therapy ("CGT") designation.
  • Leucadia\'s products include Calcitonin Salmon Injection, USP, Synthetic, Acetaminophen Injection, Dihydroergotamine Mesylate Nasal Spray, Icatibant Injection, Sodium Tetradecyl Sulfate (STS) Injection, 3%, Valrubicin Intravesical Solution, USP, Pentobarbital Sodium Injection, USP and Fludarabine Phosphate for Injection, USP.

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Retrieved on: 
Wednesday, May 19, 2021
Clinical medicine, Medicine, Endocrinology, Diabetes, Insulin pump, Peptide hormones, Recombinant proteins, Insulin, Bolus, Intensive insulin therapy, Untethered regimen

The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.

Key Points: 
  • The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.
  • "Controlling an insulin pump and viewing its status via smartphone allows people with diabetes to use a device which is usually close at hand.
  • Using the mySugr Pump Control provides people with diabetes more discretion and simplicity with their everyday insulin pump therapy.
  • Users of the mySugr Pump Control are also able to get support from the mySugr Bolus Calculator, which calculates the needed amount of insulin for meal and correction boluses.

Roche launches mySugr Pump Control within the mySugr app to simplify insulin pump therapy via smartphone

Retrieved on: 
Wednesday, May 19, 2021
Clinical medicine, Medicine, Endocrinology, Diabetes, Insulin pump, Peptide hormones, Recombinant proteins, Insulin, Bolus, Intensive insulin therapy, Untethered regimen

The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.

Key Points: 
  • The mySugr Pump Control is designed to enable people with diabetes to control an insulin pump directly via a smartphone: import its data, view its status, and remotely deliver a standard bolus.
  • "Controlling an insulin pump and viewing its status via smartphone allows people with diabetes to use a device which is usually close at hand.
  • Using the mySugr Pump Control provides people with diabetes more discretion and simplicity with their everyday insulin pump therapy.
  • Users of the mySugr Pump Control are also able to get support from the mySugr Bolus Calculator, which calculates the needed amount of insulin for meal and correction boluses.

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Retrieved on: 
Monday, May 17, 2021
Branches of biology, Peptide hormones, Organ systems, Hormones, Communication, Forward-looking statement, Ghrelin, Amyotrophic lateral sclerosis

It is also licensed to Consilient Health Ltd. for the European Economic Area and United Kingdom, and Megapharm Ltd. for Israel and the Palestinian Authority.

Key Points: 
  • It is also licensed to Consilient Health Ltd. for the European Economic Area and United Kingdom, and Megapharm Ltd. for Israel and the Palestinian Authority.
  • Its level is often reduced in ALS patients and stimulation of GH excretion improves survival in ALS mouse models.
  • Dr. Steyn\xe2\x80\x99s research team at The University have confirmed these positive effects of ghrelin mimetics in several experiments.
  • Given the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements.

Mashantucket Pequot Tribal Nation’s Partnership with Virta Health Shows Unprecedented Progress In Reversing the Community’s Type 2 Diabetes Epidemic

Retrieved on: 
Tuesday, May 11, 2021
Diabetes, General Health, Pharmaceutical, Health, Clinical medicine, Branches of biology, Medicine, Algonquian peoples, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Pequots, Mashantucket Pequot Tribe, Type 2 diabetes, Medical prescription

b"Today, Virta Health , the type 2 diabetes reversal leader, announced one-year patient outcomes from its multi-year partnership with Mashantucket Pequot Tribal Nation , with promising results in A1c reduction, weight loss, and insulin de-prescription.

Key Points: 
  • b"Today, Virta Health , the type 2 diabetes reversal leader, announced one-year patient outcomes from its multi-year partnership with Mashantucket Pequot Tribal Nation , with promising results in A1c reduction, weight loss, and insulin de-prescription.
  • Notably, at one year of the Virta Treatment, Pequot patients reduced their insulin prescriptions by 78%.
  • At two years, the Pequot Nation reduced its total medication spend by 50%, amounting to over $3800 per patient per year.
  • Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts.

Bigfoot Biomedical® Receives FDA Clearance for Bigfoot Unity™ Diabetes Management System, Featuring First-of-its-Kind Smart Pen Caps for Insulin Pens used to Treat Type 1 and Type 2 Diabetes

Retrieved on: 
Monday, May 10, 2021
Technology, Pharmaceutical, Venture capital, Teens, Medical devices, Hospitals, Fitness & Nutrition, Finance, Biotechnology, Professional services, Health, Women, Seniors, Practice Management, Managed care, MEN, Consumer, Medical Supplies, Software, FDA, Diabetes, Hardware, Data management, Clinical medicine, Medicine, Branches of biology, Medical monitoring, Bigfoot Biomedical, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Diabetes management, Bigfoot, Bigfoot Biomedical, Inc., Bigfoot Biomedical CEO Jeffrey Brewer, BIGFOOT BIOMEDICAL, INC., BIGFOOT BIOMEDICAL CEO JEFFREY BREWER

The Bigfoot Unity smart pen caps provide on-demand, insulin dose decision support to minimize guesswork and enable patients to follow their doctor\xe2\x80\x99s instructions in a convenient, simple way.

Key Points: 
  • The Bigfoot Unity smart pen caps provide on-demand, insulin dose decision support to minimize guesswork and enable patients to follow their doctor\xe2\x80\x99s instructions in a convenient, simple way.
  • The Bigfoot Unity System features first-of-its-kind smart pen caps that display insulin dose recommendations on demand, so users can follow their doctor\xe2\x80\x99s instructions in a convenient, simple way.
  • "Through Abbott\'s collaboration with Bigfoot Biomedical, we\'re integrating our revolutionary, easy-to-use FreeStyle Libre 2 technology with the Bigfoot Unity System to provide automated information for personalized diabetes management.
  • The smart pen cap also directly displays the health care provider\xe2\x80\x99s suggested meal insulin doses with the correction dose.

Glooko Announces Digital Health Collaboration with Eli Lilly's Connected Insulin Pen Solutions in Global Markets

Retrieved on: 
Thursday, May 6, 2021
Clinical medicine, Branches of biology, Medicine, Diabetes, Peptide hormones, Recombinant proteins, Insulin, Diabetes management, Glooko, Injector pen, Diabetes management software, Intensive insulin therapy

The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.

Key Points: 
  • The integrated and actionable insights available in Glooko will improve the standard of diabetes care.\n"Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch," said Russ Johannesson, CEO of Glooko.
  • "Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes.
  • "Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses.
  • By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.